CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression.

ABSTRACT: Glioblastoma (GBM) is the most common primary brain tumor, yet prognosis remains dismal with current treatment. Immunotherapeutic strategies have had limited effectiveness to date in GBM, but recent advances hold promise. One such immunotherapeutic advance is chimeric antigen receptor (CAR) T cell therapy, where autologous T cells are extracted and engineered to express a specific receptor against a GBM antigen and are then infused back into the patient. There have been numerous preclinical studies showing promising results, and several of these CAR T cell therapies are being tested in clinical trials for GBM and other brain cancers. While results in tumors such as lymphomas and diffuse intrinsic pontine gliomas have been encouraging, early results in GBM have not shown clinical benefit. P

SUBMITTER: Luksik AS 

PROVIDER: S-EPMC10000604 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature